Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells

被引:174
作者
Hengstermann, A
Linares, LK
Ciechanover, A
Whitaker, NJ
Scheffner, M
机构
[1] Univ Cologne, Fac Med, Inst Biochem 1, D-50931 Cologne, Germany
[2] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel
关键词
D O I
10.1073/pnas.031470698
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The E6 oncoprotein of human papillomaviruses (HPVs) that are associated with cervical cancer utilizes the cellular ubiquitin-protein ligase EG-AP to target the tumor suppressor p53 for degradation. In normal cells (i.e., in the absence of E6), p53 is also a target of the ubiquitin-proteasome pathway. Under these conditions, however, p53 degradation is mediated by Mdm2 rather than by EG-AP. Here we show in a mutational analysis that, surprisingly, the structural requirements of p53 to serve as a proteolytic substrate differ between E6 proteins derived from different HPV types and, as expected, between Mdm2 and E6 proteins in vitro and in vivo. Stable expression of such mutants in HPV-negative and HPV-positive cell lines demonstrates that in HPV-positive cancer cells, the EG-dependent pathway of p53 degradation is not only active but, moreover, is required for degradation of p53, whereas the Mdm2-dependent pathway is inactive. Because the p53 pathway was reported to be functional in HPV-positive cancer cells, this finding indicates clearly that the ability of the E6 oncoprotein to target p53 for degradation is required for the growth of HPV-positive cancer cells.
引用
收藏
页码:1218 / +
页数:7
相关论文
共 40 条
[1]   Regulation of p53 stability [J].
Ashcroft, M ;
Vousden, KH .
ONCOGENE, 1999, 18 (53) :7637-7643
[2]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[3]   Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells [J].
BeerRomero, P ;
Glass, S ;
Rolfe, M .
ONCOGENE, 1997, 14 (05) :595-602
[4]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[5]   Molecular characterization of the hdm2-p53 interaction [J].
Bottger, A ;
Bottger, V ;
GarciaEcheverria, C ;
Chene, P ;
Hochkeppel, HK ;
Sampson, W ;
Ang, K ;
Howard, SF ;
Picksley, SM ;
Lane, DP .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 269 (05) :744-756
[6]   Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein [J].
Butz, K ;
Denk, C ;
Ullmann, A ;
Scheffner, M ;
Hoppe-Seyler, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6693-6697
[7]  
BUTZ K, 1995, ONCOGENE, V10, P927
[8]  
Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO
[9]  
2-2
[10]   INTERACTION OF PAPILLOMAVIRUS E6 ONCOPROTEINS WITH A PUTATIVE CALCIUM-BINDING PROTEIN [J].
CHEN, JJ ;
REID, CE ;
BAND, V ;
ANDROPHY, EJ .
SCIENCE, 1995, 269 (5223) :529-531